Incyte: Stifel raises target price to $157 from $145
INCY•Stifel raised its target price for Incyte to $157 from $145.
Related News
Nurix extends Gilead collaboration for oncology program
NRIX•
GEO Group sells three Adelanto ICE facilities to US government for $950 million
GEO•
Wabash schedules third-quarter 2026 earnings conference call webcast
WNC•
Lumexa Imaging Holdings initiates coverage with buy rating; price target $18
LMRI•
Stoke Therapeutics targets early 2028 U.S. launch for Dravet drug zorevunersen after FDA alignment meeting
STOK•